We are pleased to be able to offer this specialized, formulated prescription internationally.
Philadelphia, PA (PRWEB) January 08, 2014
In a move to expand its geographic reach to international markets and further implement the strategic growth plan of the company, Pentec Health, Inc. today announced that it has been awarded a patent by the Intellectual Property Office of Australia for its specialty pharmacy compounded prescription renal formulation, PROPLETE®. Proplete® is a proprietary Intradialytic Parenteral Nutrition (IDPN) supplement that is effective in the nephrologists’ treatment of malnutrition in patients receiving hemodialysis for chronic kidney disease.
According to the Australia & New Zealand Dialysis and Transplant Registry (ANZDATA 2012 Report), as of December 31, 2011, there were 8,929 patients receiving hemodialysis for Chronic Kidney Disease in Australia. This is an increase in the maintenance hemodialysis (MHD) population of 4% since December 31, 2010.
Along with Hong Kong and the United Kingdom, this marks the company’s third patent award. “Pentec's geographic expansion is viewed by the company as an engine for future growth, the Australian patent enables us to extend our global reach even further,” explains Joseph Cosgrove, Chairman, President and CEO of Pentec Health. “Nephrologists around the world will now have access to an extremely powerful tool in treating malnutrition in their dialysis patients. We are pleased to be able to offer this specialized, formulated prescription internationally.”
In addition to treating malnutrition in dialysis patients, the compound may also reduce the need for insulin administration for patients undergoing maintenance hemodialysis. Furthermore, this supplement may benefit patients with metabolic conditions that impair their glucose tolerance or patients with strict fluid management.
Eileen Moore, CNSC, RD LD, Renal Program Clinical Director at Pentec Health, commented on what makes Proplete® unique. “New Proplete® solutions help alleviate problems inherent in conventional IDPN solutions such as hyperglycemia, volume challenges, and pro-inflammatory substrate inclusion while improving serum albumin levels.”
Pentec is currently pursuing patents for PROPLETE® in multiple other countries, including the United States. Pentec's compounding services are available in all 50 U.S. states.
About Pentec Health, Inc.
Pentec Health, Inc. is a privately-held national provider of proprietary nutritional infusion therapies for patients suffering from chronic kidney disease and offers specialized pharmacy and nursing services for patients with implanted drug delivery pumps treating severe pain and spasticity. The company is headquartered in suburban Philadelphia and is proud to be celebrating its 30th year in business. The Joint Commission has consistently awarded Pentec with its Gold Seal of Approval for their commitment to providing the highest level of patient safety and patient care for renal nutrition and specialty infusion home care services. For more information, visit http://www.pentechealth.com.